Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone acetonide extended-release injectable suspension
- Development stage
- Approved
- Lead developer
- Pacira BioSciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intraarticular
01
Overview
ZILRETTA is an extended-release formulation of the synthetic corticosteroid triamcinolone acetonide, designed as a microsphere-based injectable suspension for intra-articular use. It is indicated for the management of osteoarthritis pain of the knee. The drug utilizes poly(lactic-co-glycolic acid) (PLGA) microspheres to provide sustained release of triamcinolone acetonide directly into synovial tissues, aiming to deliver prolonged pain relief compared to immediate-release corticosteroid injections. After administration, the microspheres gradually degrade into carbon dioxide and water. ZILRETTA is not intended for repeat administration and should not be used in small joints or by routes other than intra-articular injection in the knee[1][3][4].
- Brand names
- ZILRETTA
- Other names
- triamcinolone acetonide extended-release injectable suspensiontriamcinolone acetonide (extended-release)
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on triamcinolone acetonide extended-release injectable suspension.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone acetonide extended-release injectable suspension.